Drug Profile
Adalimumab biosimillar - Huaota Biopharmaceuticals
Alternative Names: HOT-3010; Onco-3010Latest Information Update: 31 Mar 2023
Price :
$50
*
At a glance
- Originator Outlook Therapeutics
- Developer Huaota Biopharmaceuticals
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Ankylosing spondylitis; Plaque psoriasis; Rheumatoid arthritis
Most Recent Events
- 31 Mar 2023 Adalimumab biosimilar (HOT 3010) is still in phase III trials for Ankylosing spondylitis, Plaque psoriasis, Rheumatoid arthritis (Parenteral) in China (Huaota Biopharmaceuticals pipeline, March 2023)
- 08 Apr 2022 Phase-III clinical trials in Ankylosing spondylitis in China (Parenteral) (Huaota Biopharmaceuticals pipeline, April 2022)
- 08 Apr 2022 Phase-III clinical trials in Plaque psoriasis in China (Parenteral) (Huaota Biopharmaceuticals pipeline, April 2022)